

EFPIA and CPIA Joint Forum to Enhance Regulatory Understanding

EFPIA and the China Pharmaceutical Industry Association (CPIA) are jointly organising a China/EU Pharmaceutical Industry Forum on 16 May 2015, at the National Exhibition and Convention Centre in Shanghai, China.

The workshop will cover a variety of themes, including: an overview of the pharmaceutical industry in China and EU; patient access to innovative drugs; the Drug Administration Law (DAL) revision; drug quality; and pharmaceutical in the environment.

EFPIA's Chief Economist, Richard Torbett will offer an overview of the pharmaceutical industry in the EU. He will discuss some of the barriers to access for innovative drugs but also some possible solutions to the challenge of health system sustainability. Richard will underscore the industry's ongoing commitment to invest in R&D and its contribution to the European economy.

Anette Hjelmshark from the EFPIA China regulatory network will give a presentation on the EU system for marketing authorisation. Among other things, she will focus on enablers facilitating development of medicines including EFPIA recommendations to separate new drug applications from the clinical trial applications.

Bengt Mattson, Co-Chair of the EFPIA Pharmaceuticals in the Environment (PIE-TF), will cover expectations from the European industry regarding collaboration on drug quality and the environment. A major theme of his presentation will be the concept of a maturity ladder, which is a stepwise approach of increasing capability.

Mr Liu Jihong from the Chinese Food and Drug Administration (CFDA), will make a presentation on the plans for reforming the Chinese Drug Administration Law, a topic that has aroused significant interest at EFPIA.

The workshop has already generated significant interest and has attracted a large number of participants both from Europe and China.

For further information, please contact Pär Tellner, EFPIA Director of Regulatory Affairs:
[+32.476.84.08.79](tel:+32476840879)